KYE™ Sector Pack Foundry™

Agentic Governance™ with Authority Finality™ for biopharma pharmacovigilance.

Every AI-assisted safety or GxP decision — ICSR causality assessment, signal detection, electronic-record signing, clinical-trial protocol-deviation handling — mapped to a named control owner, bound to the obligation it discharges, and signed into an Evidence Pack™ at the moment it happens. The Biopharma Pharmacovigilance Authority Pack™ is the KYE™ Sector Pack Foundry™ productisation that lands Agentic Governance™ — every act has authority, every authority has finality — inside EMA GVP, MHRA, FDA 21 CFR Part 11, and ICH E6(R3) GCP-regulated firms.

Apply via the FoundrySee the 8-step pipelineBound regulatory perimeter

KYE™ Biopharma Pharmacovigilance Authority Pack™, at a glance

Demo data

You learn: What this pack governs and how. You can: Run through it.

  1. EMA Good Pharmacovigilance Practices (GVP Module VI / Module IX)

    KYE Protocol™

  2. MHRA pharmacovigilance supervision

    KYE Protocol™

  3. FDA 21 CFR Part 11 (electronic records and electronic signatures)

    KYE Protocol™

  4. ICH E6(R3) Good Clinical Practice

    KYE Protocol™

How this widget is built
Demonstrates
KYE™ authority packs
Components
  • The regulated actions
  • Their authority
  • Their evidence
Flow
Each action the pack governs, in order. Architecture diagram
Used on

EMA GVP, MHRA, FDA 21 CFR Part 11, ICH E6(R3) GCP — the biopharma safety and GxP perimeter.

Marketing-authorisation holders, clinical-trial sponsors, and CROs running AI agents across pharmacovigilance and GxP conduct are inside a named-accountability perimeter — Qualified Person for Pharmacovigilance sign-off, signal-management evidence, electronic-record integrity, and investigator authority over protocol deviations. AI-assisted safety operations need named-owner accountability and signed, replay-derivable evidence per decision.

Better evidence than reconstructed logs — signed at the moment, derivable from public keys alone.

The dominant evidence today is after-the-fact reconstruction. A KYE Protocol™ Evidence Pack™ plus Authority Finality™ outcome bound to the named control owner, the obligation discharged, and the delegation chain is materially better evidence: signed at the moment of the decision and Replay-Proof™ against the published JWKS a regulator or inspector can verify offline.

An 8-step pipeline — from AI decision to safety / quality view.

The Pack rides the canonical productisation shape: rule pack, dictionary, sector pack, obligation manifest, expert-pack envelope, coverage attestation, SKU row, and this marketing surface. No Foundry-specific framework shape; the protocol evidence layer underneath is identical to every other Pack.

Bound to the canonical biopharma safety and GxP perimeter.

  • EMA Good Pharmacovigilance Practices (GVP Module VI / Module IX)
  • MHRA pharmacovigilance supervision
  • FDA 21 CFR Part 11 (electronic records and electronic signatures)
  • ICH E6(R3) Good Clinical Practice

Regulators of record: EMA / MHRA / FDA.

Qualified partners — apply through the Foundry.

Apply via the FoundrySee the three Foundry tiersBound regulatory frameworks